Cubist Pharmaceuticals Company Profile (NASDAQ:CBST)

About Cubist Pharmaceuticals (NASDAQ:CBST)

Cubist Pharmaceuticals logoCubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. As of December 31, 2011, the Company had two marketed products, CUBICIN (daptomycin for injection) and ENTEREG (alvimopan). The Company also co-promotes DIFICIDTM in the United States, under its co-promotion agreement with Optimer Pharmaceuticals, Inc. (Optimer). In September 2013, the Company announced that it has completed the acquisition of Trius Therapeutics Inc. In October 2013, the Company announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CBST
  • CUSIP: 22967810
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $101.00
  • 200 Day Moving Avg: $85.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 52.55
  • P/E Growth: 0
Dividend:
  • Dividend Yield: 1.0%
 
Frequently Asked Questions for Cubist Pharmaceuticals (NASDAQ:CBST)

What is Cubist Pharmaceuticals' stock symbol?

Cubist Pharmaceuticals trades on the NASDAQ under the ticker symbol "CBST."

How were Cubist Pharmaceuticals' earnings last quarter?

Cubist Pharmaceuticals Inc (NASDAQ:CBST) posted its quarterly earnings data on Tuesday, October, 21st. The company reported $0.58 EPS for the quarter, beating the consensus estimate of $0.04 by $0.54. The firm earned $309.20 million during the quarter, compared to analysts' expectations of $305.50 million. Cubist Pharmaceuticals's revenue for the quarter was up 16.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.41 EPS. View Cubist Pharmaceuticals' Earnings History.

Who are some of Cubist Pharmaceuticals' key competitors?

How do I buy Cubist Pharmaceuticals stock?

Shares of Cubist Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cubist Pharmaceuticals' stock price today?

One share of Cubist Pharmaceuticals stock can currently be purchased for approximately $101.94.


MarketBeat Community Rating for Cubist Pharmaceuticals (NASDAQ CBST)
Community Ranking:  2.4 out of 5 ( )
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  168 (Vote Underperform)
Total Votes:  327
MarketBeat's community ratings are surveys of what our community members think about Cubist Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cubist Pharmaceuticals (NASDAQ:CBST) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Cubist Pharmaceuticals (NASDAQ:CBST)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Cubist Pharmaceuticals (NASDAQ:CBST)
Earnings by Quarter for Cubist Pharmaceuticals (NASDAQ:CBST)
Earnings History by Quarter for Cubist Pharmaceuticals (NASDAQ CBST)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/21/2014Q314$0.04$0.58$305.50 million$309.20 millionViewListenView Earnings Details
7/22/2014Q214$0.37$0.23$299.60 million$294.40 millionViewN/AView Earnings Details
4/22/2014Q114$0.34$0.10$285.24 million$261.20 millionViewN/AView Earnings Details
1/23/2014Q413$0.33$0.29$285.47 million$299.70 millionViewN/AView Earnings Details
7/18/2013Q2 2013$0.55$0.42$254.93 million$258.80 millionViewN/AView Earnings Details
4/18/2013Q1 2013$0.50$0.34$243.55 million$229.90 millionViewN/AView Earnings Details
1/23/2013Q4 2012$0.48$0.51$246.42 million$245.90 millionViewN/AView Earnings Details
10/18/2012$0.47$0.55ViewN/AView Earnings Details
7/19/2012$0.45$0.68ViewN/AView Earnings Details
4/18/2012$0.63$0.82ViewN/AView Earnings Details
1/19/2012$0.31$0.11ViewN/AView Earnings Details
10/19/2011$0.26$0.33ViewN/AView Earnings Details
7/14/2011$0.43($0.34)ViewN/AView Earnings Details
4/14/2011$0.26$0.34ViewN/AView Earnings Details
1/20/2011$0.34$0.24ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cubist Pharmaceuticals (NASDAQ:CBST)
Current Year EPS Consensus Estimate: $1.14 EPS
Next Year EPS Consensus Estimate: $1.94 EPS

Dividends

Dividend History for Cubist Pharmaceuticals (NASDAQ:CBST)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cubist Pharmaceuticals (NASDAQ:CBST)
Insider Trades by Quarter for Cubist Pharmaceuticals (NASDAQ:CBST)
Insider Trades by Quarter for Cubist Pharmaceuticals (NASDAQ:CBST)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/1/2014Steven C GilmanEVPSell48,125$65.39$3,146,893.75View SEC Filing  
8/19/2014Gregory SteaSVPSell38,326$65.88$2,524,916.88View SEC Filing  
8/18/2014Nancy J HutsonDirectorSell9,000$65.00$585,000.00View SEC Filing  
8/18/2014Robert J PerezCOOSell1,003$63.68$63,871.04View SEC Filing  
7/28/2014Steven C GilmanEVPSell40,625$61.57$2,501,281.25View SEC Filing  
5/15/2014Michael BonneyCEOSell3,036$67.50$204,930.00View SEC Filing  
5/15/2014Robert PerezCOOSell1,518$67.50$102,465.00View SEC Filing  
5/15/2014Steven GilmanEVPSell16,340$67.82$1,108,178.80View SEC Filing  
5/14/2014Michael BonneyCEOSell3,840$69.00$264,960.00View SEC Filing  
5/14/2014Robert PerezCOOSell2,400$69.00$165,600.00View SEC Filing  
5/14/2014Steven GilmanEVPSell1,680$69.00$115,920.00View SEC Filing  
3/6/2014Gregory SteaSVPSell19,889$79.74$1,585,948.86View SEC Filing  
2/27/2014Mark CorriganDirectorSell5,000$80.00$400,000.00View SEC Filing  
2/27/2014Michael BonneyCEOSell100,000$81.25$8,125,000.00View SEC Filing  
2/27/2014Robert PerezCOOSell30,000$80.18$2,405,400.00View SEC Filing  
2/20/2014Michael BonneyCEOSell3,112$75.60$235,267.20View SEC Filing  
2/3/2014Kenneth BateDirectorSell6,250$72.15$450,937.50View SEC Filing  
1/15/2014Gregory SteaSVPSell5,312$74.90$397,868.80View SEC Filing  
1/15/2014Robert PerezCOOSell10,000$74.95$749,500.00View SEC Filing  
1/13/2014Robert PerezCOOSell10,000$72.95$729,500.00View SEC Filing  
1/9/2014Kenneth BateDirectorSell10,000$70.00$700,000.00View SEC Filing  
1/2/2014Steven GilmanEVPSell25,000$67.82$1,695,500.00View SEC Filing  
12/2/2013Kenneth BateDirectorSell12,500$67.63$845,375.00View SEC Filing  
9/9/2013Martin RosenbergDirectorSell15,472$65.00$1,005,680.00View SEC Filing  
8/16/2013Robert PerezCOOSell1,024$60.55$62,003.20View SEC Filing  
7/31/2013Gregory SteaSVPSell33,750$61.29$2,068,537.50View SEC Filing  
7/26/2013Nancy J HutsonDirectorSell5,000$53.87$269,350.00View SEC Filing  
7/19/2013Gregory SteaSVPSell4,375$55.00$240,625.00View SEC Filing  
6/3/2013Kenneth BateDirectorSell2,500$54.95$137,375.00View SEC Filing  
6/3/2013Steven C GilmanEVPSell15,125$54.49$824,161.25View SEC Filing  
5/24/2013Mark CorriganDirectorSell14,000$54.60$764,400.00View SEC Filing  
5/22/2013J Matthew SingletonDirectorSell27,500$55.48$1,525,700.00View SEC Filing  
5/20/2013Charles Anthony LaranjeiraSVPSell14,000$51.43$720,020.00View SEC Filing  
5/20/2013Michael W BonneyCEOSell60,000$50.00$3,000,000.00View SEC Filing  
5/20/2013Robert J PerezCOOSell15,000$49.98$749,700.00View SEC Filing  
5/16/2013Michael W BonneyCEOSell2,400$47.88$114,912.00View SEC Filing  
5/16/2013Robert J PerezCOOSell1,500$47.88$71,820.00View SEC Filing  
5/16/2013Steven C GilmanEVPSell1,201$48.88$58,704.88View SEC Filing  
5/15/2013Kenneth BateDirectorSell2,500$48.41$121,025.00View SEC Filing  
5/15/2013Michael W BonneyCEOSell2,979$48.41$144,213.39View SEC Filing  
5/15/2013Robert J PerezCOOSell1,490$48.41$72,130.90View SEC Filing  
5/15/2013Steven C GilmanEVPSell1,017$48.41$49,232.97View SEC Filing  
5/14/2013Michael W BonneyCEOSell3,753$49.18$184,572.54View SEC Filing  
5/14/2013Robert J PerezCOOSell2,346$49.18$115,376.28View SEC Filing  
5/14/2013Steven C GilmanEVPSell1,135$49.18$55,819.30View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cubist Pharmaceuticals (NASDAQ:CBST)
Latest Headlines for Cubist Pharmaceuticals (NASDAQ:CBST)
Source:
DateHeadline
finance.yahoo.com logoMario Gabelli's Top 5 Stock Picks
finance.yahoo.com - March 31 at 3:50 AM
finance.yahoo.com logoFarallon Capital Starts New Position in Cubist Pharmaceuticals
finance.yahoo.com - March 20 at 4:06 PM
finance.yahoo.com logoElliott Management exits position in Covidien
finance.yahoo.com - March 4 at 6:05 PM
finance.yahoo.com logoElliott Management starts new position in Cubist Pharmaceuticals
finance.yahoo.com - March 2 at 6:05 PM
finance.yahoo.com logoPrem Watsa's Stock Buys and Sells of Q4
finance.yahoo.com - February 17 at 12:08 AM
finance.yahoo.com logoDana Holding Set to Join the S&P MidCap 400
finance.yahoo.com - January 20 at 5:45 PM
finance.yahoo.com logoFDA approves Cubists' drug for antibiotic-resistant bacteria
finance.yahoo.com - December 19 at 6:07 PM
finance.yahoo.com logoCubist sales force seen as potential boon for Merck intestinal drug
finance.yahoo.com - December 10 at 8:50 AM
finance.yahoo.com logoMerck says still plans Cubist purchase, despite patent setback
finance.yahoo.com - December 9 at 8:59 AM
247wallst.com logoAfter Big Cubist Buy, Are These 2 Stocks Next to Be Acquired?
247wallst.com - December 9 at 8:50 AM
latimes.com logoMerck to buy Cubist Pharmaceuticals for $8.4 billion
www.latimes.com - December 8 at 6:09 PM
finance.yahoo.com logoCourt rules Hospira can launch generic Cubicin in 2016
finance.yahoo.com - December 8 at 5:39 PM
uk.finance.yahoo.com logoUS STOCKS-Wall St falls with energy shares; global data disappoints
uk.finance.yahoo.com - December 8 at 1:46 PM
finance.yahoo.com logoCubist options unusually active before Merck deal
finance.yahoo.com - December 8 at 12:54 PM
finance.yahoo.com logoUS STOCKS-Wall St flat after Japan, China data; biotechs climb
finance.yahoo.com - December 8 at 11:13 AM
finance.yahoo.com logoUS STOCKS-Wall St slips after Japan, China data; energy drags
finance.yahoo.com - December 8 at 9:54 AM
finance.yahoo.com logoUS STOCKS-Wall St to open lower after Japan, China data
finance.yahoo.com - December 8 at 9:10 AM
247wallst.com logoMerck, Cubist Agree to $9.5 Billion Acquisition
247wallst.com - December 8 at 8:20 AM

Social

Chart

Cubist Pharmaceuticals (CBST) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff